Sarah Simon

“So first of all, just on back on Lysol again. Chris, you said that this occurred late in the quarter. Can you give us an idea of kind of what the selling rate was running at before this impacted?”

“Most of my questions have been answered, but just one. Can you give us the weighting of cold and flu revenue through the quarters? That would be helpful.”

“Most of my questions have been answered, but just one. Can you give us the weighting of cold and flu revenue through the quarters? That would be helpful.”

“First one is, just can you remind us, like for like, is that assuming that what you own now you owned last year, or is it excluding the contribution of everything that's been acquired until you get to a year afterwards I'm just thinking because obviously you've got some bigger M&A coming in and then the second…”

“How important is it in terms of securing shelf space and sort of with your retailer negotiations to have that cold and flu business? Because I think, you know, in your bid to become a sort of steady compounder with predictable top line, this is obviously the kind of bit that's causing the biggest issue.”